Cardiomyopathy Clinical Trials

The cardiomyopathy clinical trials team is interested in seeing how exciting new cardiomyopathy drugs and devices can help to improve the outcomes and quality of life for those living with the cardiomyopathy disease.

Feel free to call or e-mail the Knight Cardiovascular Institute research team at 503-418-1964 or by emailing . You will then be forwarded to the appropriate research team member who will be able to see if you qualify for any of the clinical trials being offered at OHSU.

You can also find all the of heart failure clinical trials, that are currently enrolling patients, below.

Clinical Trial Name

Principal Investigator

Sub Investigators

Protocol Number

 BeAT-HF: Barostim Neo® - Baroflex Activation Therapy for Heart FailureAlbert Camacho, MD
CAPACITY-HF: - A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study Evaluating the Safety and Efficacy of Different Doses of IW-1973 over 12 Weeks in Patients with Heart Failure with Preserved Ejection Fraction (CAPACITY HFpEF)
Albert Camacho, MD
Catherine Wong, MD / Jayne Mitchell, ANP-BC, CHFN
HCM Pilot Study: Hypertrophic Cardiomyopathy Pilot StudyLarisa Tereshchenko, MD, PhDStephen Heitner, MDIRB00015049
LIFE STUDY: Entresto™(LCZ696) in Advance Heart FailureAlbert Camacho, MD
MAVERICK-HCM: A Randomized, Double-blind, Pacebo-controlled, Concentration-guided, Exploratory Study of Mavacamten (MYK-461) in Patients with Symptomatic Non-obstructive Hypertrophic Cardiomyopathy (nHCM) and Preserved Left Ventricular Ejection FractionStephen Heitner, MDBabak Nazer, MD / Erin Boehm, MD / Katherine Bischof, PA-C / Lidija Breznikar McGrath, MD / Michael Shapiro, DO / Mrinal Yadava, MD / Ryan Von Woerkom, MD / Steven Mansoor, MD, PhD / Thomas Dewland, MD / Vaughn Tuchy, MDIRB00018173

MOMENTUM 3: Multi-Center Study of Maglev Technology in Patients Undergoing MCS Therapy in HeartMate 3

Frederick Tibayan, MD

MYK-491-003 HF-SAD: Randomized, Double-blind, Crossover, Placebo-controlled, Adaptive Design Study of Safety, Tolerability, Preliminary Pharmacokinetics, and Pharmacodynamics of Single Ascending Oral Doses of MYK-491 in Patients with Stable Heart Failure

Albert Camacho, MD
Stephen Heitner, MD